HALOZYME THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
HALOZYME THERAPEUTICS, INC. (HALO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $467.53 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-17
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $467.53M, a 16.19% decline from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $557.85M, a 59.92% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $348.83M, a 40.14% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $248.92M, a 0.34% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $467.53M 10-K · filed 2026-02-17 |
| 2024-12-31 | $557.85M 10-K · filed 2026-02-17 |
| 2023-12-31 | $348.83M 10-K · filed 2026-02-17 |
| 2022-12-31 | $248.92M 10-K · filed 2025-02-18 |
| 2021-12-31 | $248.07M 10-K · filed 2024-02-20 |
| 2020-12-31 | $130.43M 10-K · filed 2023-02-21 |
| 2019-12-31 | -$70.74M 10-K · filed 2022-02-22 |
| 2018-12-31 | -$45.82M 10-K · filed 2021-02-23 |
| 2017-12-31 | $160.94M 10-K · filed 2020-02-24 |
| 2016-12-31 | $6.38M 10-K · filed 2019-02-21 |
| 2015-12-31 | $11.72M 10-K · filed 2018-02-20 |
| 2014-12-31 | -$30.89M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |